| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
Purity: ≥98%
Nizatidine (Tazac, Axid, LY-139037, LY 139037, LY139037) is a potent histamine H2 receptor antagonist used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. Its IC50 value for the histamine H2 receptor is 0.9 nM.
Nizatidine is a histamine H2-receptor antagonist (H2 blocker) belonging to the thiazole derivative class. Its chemical name is N-[2-[[[2-[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine, with the molecular formula C₁₂H₂₁N₅O₂S₂ and a molecular weight of 331.46. It is primarily indicated for the treatment of peptic ulcer disease, gastroesophageal reflux disease (GERD), and maintenance therapy for healed duodenal ulcers. Compared to older H2 receptor antagonists such as cimetidine, nizatidine exhibits no antiandrogenic effects and does not interfere with hepatic drug metabolism, offering an improved tolerability and safety profile.| Targets |
Histamine H2 receptor ( IC50 = 0.9 nM ); AChE ( IC50 = 6.7 μM )
Histamine H2 receptor (H2R) (human H2R, Ki=3.3 nM; rat H2R, Ki=4.8 nM) [1] Histamine H1 receptor (H1R) (Ki>1000 nM, negligible affinity) [1] |
|---|---|
| ln Vitro |
In vitro activity: Nizatidine, a selective histamine H2-receptor antagonist, has an IC50 of 0.9 nM and is a strong inhibitor of gastric acid secretion.[1] Nizatidine additionally and noncompetitively inhibits acetylcholinesterase (AChE) with a Ki value of 7.4 μM and an IC50 of 6.7 μM. [2]
Isolated canine parietal cells were stimulated with histamine (10 μM) to induce acid secretion. Nizatidine (0.1 μM-10 μM) dose-dependently inhibited acid secretion, with an IC50 of 0.6 μM, confirming competitive H2R antagonism [1] - Radioligand binding assay with rat gastric mucosal membrane fractions showed Nizatidine specifically bound to H2R, displacing [3H]-tiotidine in a concentration-dependent manner, with no significant binding to H1R [1] - Cultured rat gastric mucosal cells were treated with Nizatidine (1 μM-50 μM) for 24 hours. The drug did not affect cell viability but inhibited histamine-induced cAMP accumulation by 60% at 10 μM [2] |
| ln Vivo |
Nizatidine shows a maximum suppression of stomach acid in rats during the first hour of medication administration (EC50 = 1.383 μmol/kg).[1] Nizatidine (0.3-3 mg/kg, i.v.) dramatically raises the motor index of gastrointestinal (GI) motility in a dose-dependent manner. Nizatidine has an ED50 and ED90 of 0.18 and 3.22 mg/kg in dogs and 2.94 and 19.6 mg/kg in rats, respectively, which means that it inhibits the secretion of stomach acid.[2]
Rat pylorus-ligated model: Oral administration of Nizatidine (5 mg/kg, 10 mg/kg, 20 mg/kg) 1 hour before pylorus ligation dose-dependently reduced gastric acid output. The 20 mg/kg dose inhibited acid secretion by 82% and decreased gastric juice volume by 45% compared to vehicle [2] - Rat histamine-induced gastric acid secretion model: Intravenous injection of Nizatidine (1 mg/kg, 3 mg/kg) inhibited histamine-stimulated acid output by 55% and 78% respectively, with the effect lasting for 4 hours [1] |
| Enzyme Assay |
Nizatidine, a selective histamine H2-receptor antagonist, is a highly effective inhibitor of gastric acid secretion, with IC50 of 0.9 nM. Nizatidine has an EC50 of 1.383 μmol/kg and shows maximal inhibition of gastric acid in rats during the first hour of medication administration. Acetylcholinesterase (AChE) is likewise reversibly inhibited by nizatidine, with an IC50 of 6.7 μM and a noncompetitive inhibition with a Ki value of 7.4 μM. In a dose-dependent manner, nizatidine (0.3–3 mg/kg, intravenously) dramatically raises the motor index of gastrointestinal (GI) motility. With ED50 and ED90 values of 0.18 and 3.22 mg/kg in dogs and 2.94 and 19.6 mg/kg in rats, respectively, nizatidine suppresses the secretion of gastric acid. H2R binding assay: Prepare membrane fractions from human H2R-expressing HEK293 cells or rat gastric mucosa. Incubate membranes with [3H]-tiotidine (0.5 nM) and various concentrations of Nizatidine (0.01 nM-100 nM) at 37°C for 60 minutes. Separate bound and free ligand by vacuum filtration through glass fiber filters. Measure radioactivity with a liquid scintillation counter and calculate Ki values using the Cheng-Prusoff equation [1] |
| Cell Assay |
Parietal cell acid secretion assay: Isolate canine parietal cells via collagenase digestion and density gradient centrifugation. Suspend cells in culture medium and pre-treat with Nizatidine (0.1 μM-10 μM) for 30 minutes. Stimulate with histamine (10 μM) for 2 hours, then measure acid secretion via [14C]-aminopyrine accumulation assay [1]
- Gastric mucosal cell cAMP assay: Seed rat gastric mucosal cells in 24-well plates and incubate for 24 hours. Pre-treat with Nizatidine (1 μM-50 μM) for 1 hour, then stimulate with histamine (10 μM) for 30 minutes. Extract cAMP and quantify via radioimmunoassay [2] |
| Animal Protocol |
Dissolved in saline; 0.5-10 μmol/kg; s.c. injection
Rat Pylorus-ligated rat experiment: Male Sprague-Dawley rats (200-250 g) were fasted for 24 hours. Nizatidine was dissolved in physiological saline and administered via oral gavage at 5 mg/kg, 10 mg/kg, 20 mg/kg. One hour later, the pylorus was ligated under anesthesia. Four hours post-ligation, rats were euthanized, gastric juice was collected to measure volume and acid output [2] - Histamine-induced acid secretion rat experiment: Male Wistar rats (180-220 g) were anesthetized with urethane. A gastric fistula was implanted to collect gastric juice. Nizatidine (1 mg/kg, 3 mg/kg) was administered via intravenous injection, followed by histamine (1 mg/kg, subcutaneous) 30 minutes later. Gastric juice was collected every 30 minutes for 4 hours to measure acid output [1] |
| ADME/Pharmacokinetics |
Absorption: Oral bioavailability is 90%; peak plasma concentration (Cmax) is reached 1-2 hours after oral administration [1]
- Distribution: Volume of distribution (Vd) is 1.5 L/kg; widely distributed in tissues, almost without crossing the blood-brain barrier [1] - Metabolism: Very little is metabolized in the liver (about 10% of the dose), and 90% is excreted unchanged [1] - Excretion: 80% of the dose is excreted in the urine (70% unchanged, 10% metabolites), and 15% is excreted in the feces. Elimination half-life (t1/2) is 1.5-2 hours [1] - Plasma protein binding: Nizatidine has a plasma protein binding rate of 30% in human plasma [1] |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Due to the low levels of nizatidine in breast milk and the small amount ingested by infants, no adverse effects are expected on breastfed infants. No special precautions are required. For newborns, more widely used histamine H2 receptor antagonists may be preferred. ◉ Effects on Breastfed Infants As of the revision date, no relevant published information was found. ◉ Effects on Lactation and Breast Milk Histamine H2 receptor antagonists are known to stimulate prolactin secretion. As of the revision date, no reports have been found of nizatidine causing hyperprolactinemia, galactorrhea, or effects on breastfeeding women. Prolactin levels in established lactating mothers may not affect their ability to breastfeed. Acute toxicity: LD50 in rats and mice > 5000 mg/kg (oral); no deaths or serious clinical symptoms (e.g., ataxia, convulsions) have been reported [1] -Chronic toxicity: No significant hepatotoxicity or hematologic abnormalities were observed in rats after oral administration of nizatidine (100 mg/kg/day) for 6 consecutive months [1] -Clinical side effects: Mild headache (3-5% of patients), diarrhea (2-3%), and nausea (1-2%) have been reported. No significant cardiovascular or central nervous system toxicity has been observed at therapeutic doses [1,2] |
| References | |
| Additional Infomation |
Nizatidine belongs to the 1,3-thiazole class of compounds, with a dimethylaminomethyl substituent at position 2 and an alkylthiomethyl substituent at position 4. It is an anti-ulcer drug, an H2 receptor antagonist, and a cholinergic drug. It belongs to the 1,3-thiazole class, C-nitro compounds, organosulfur compounds, tertiary amine compounds, and carboxymidine compounds.
Nizatidine is a competitive, reversible histamine H2 receptor antagonist with antacid activity. Nizatidine inhibits histamine H2 receptors located on the basolateral membrane of gastric parietal cells, thereby reducing basal and nocturnal gastric acid secretion, resulting in reduced gastric volume, acidity, and responsiveness to stimulation. A low-toxicity histamine H2 receptor antagonist that inhibits gastric acid secretion. This drug is used to treat duodenal ulcers. See also: Nizatidine (note moved to). Nizatidine is a selective histamine H2 receptor antagonist primarily used to inhibit gastric acid secretion [1,2]. Its mechanism of action includes competitive binding to H2 receptors on parietal cells, thereby blocking histamine-induced gastric acid secretion, cAMP accumulation, and proton pump activation [1,2]. Indications include peptic ulcers, gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and prevention of stress-induced gastric ulcers [1]. It has no significant affinity for H1 receptors, muscarinic receptors, or adrenergic receptors, thus exhibiting minimal anticholinergic or sedative side effects [1]. It is rapidly absorbed and has a short elimination half-life, therefore twice-daily administration is recommended for optimal efficacy. [1] |
| Molecular Formula |
C12H21N5O2S2
|
|
|---|---|---|
| Molecular Weight |
331.46
|
|
| Exact Mass |
331.113
|
|
| Elemental Analysis |
C, 43.48; H, 6.39; N, 21.13; O, 9.65; S, 19.35
|
|
| CAS # |
76963-41-2
|
|
| Related CAS # |
Nizatidine-d3; 1246833-99-7
|
|
| PubChem CID |
3033637
|
|
| Appearance |
Off-white to light yellow-brown solid powder
|
|
| Density |
1.2±0.1 g/cm3
|
|
| Boiling Point |
478.2±45.0 °C at 760 mmHg
|
|
| Melting Point |
130-132ºC
|
|
| Flash Point |
243.0±28.7 °C
|
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
|
| Index of Refraction |
1.592
|
|
| LogP |
1.18
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
8
|
|
| Rotatable Bond Count |
9
|
|
| Heavy Atom Count |
21
|
|
| Complexity |
349
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
S(C([H])([H])C1=C([H])SC(C([H])([H])N(C([H])([H])[H])C([H])([H])[H])=N1)C([H])([H])C([H])([H])N([H])/C(=C(\[H])/[N+](=O)[O-])/N([H])C([H])([H])[H]
|
|
| InChi Key |
SGXXNSQHWDMGGP-IZZDOVSWSA-N
|
|
| InChi Code |
InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+
|
|
| Chemical Name |
(E)-1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.5 mg/mL (10.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.5 mg/mL (10.56 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 35.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.5 mg/mL (10.56 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: Saline: 30 mg/mL Solubility in Formulation 5: 50 mg/mL (150.85 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0170 mL | 15.0848 mL | 30.1696 mL | |
| 5 mM | 0.6034 mL | 3.0170 mL | 6.0339 mL | |
| 10 mM | 0.3017 mL | 1.5085 mL | 3.0170 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00486005 | Completed | Drug: Nizatidine Drug: Placebo |
Schizophrenia | Eli Lilly and Company | February 2003 | Phase 4 |
| NCT00373334 | Completed | Drug: nizatidine (axid) Drug: placebo |
GERD Heartburn |
Braintree Laboratories | August 2006 | Phase 3 |
| NCT02232308 | Completed | Drug: Nizatidine Drug: Lisinopril Drug: Placebo |
Gastroparesis | Adil Bharucha | July 2014 | Phase 1 |
| NCT01161927 | Completed | Drug: Nizatidine Drug: Axid |
Healthy | Dr. Reddy's Laboratories Limited |
July 2004 | Phase 1 |
| NCT01409395 | Completed | Drug: Metformin and nizatidine Drug: Metformin |
Healthy | University of California, San Francisco | September 2011 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA